by barry101 | Aug 7, 2023 | Press Releases
HOUSTON, Aug. 7, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it is investigating...
by barry101 | Aug 3, 2023 | Press Releases
HOUSTON, Aug. 3, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Jul 13, 2023 | Press Releases
Data published in peer-reviewed British Journal of Cancer Research No evidence of cardiotoxicity in any subject treated in this study, including up to 16 subjects whose cumulative anthracycline dose (Annamycin included) exceeded the lifetime cumulative doxorubicin (or...
by barry101 | Jul 6, 2023 | Press Releases
Live moderated video webcast on Wednesday, July 12th at 3:00 PM ET HOUSTON, July 6, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug...
by barry101 | Jun 13, 2023 | Press Releases
Live webcast fireside chat on Wednesday, June 21st at 1:30 PM ET HOUSTON, June 13, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs,...
by barry101 | May 30, 2023 | Press Releases
– Company urges shareholders of record date, March 27, 2023, to vote your shares immediately if you have not already done so HOUSTON, May 30, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical...
